Rhenium (186Re) obisbemeda (rhenium nanoliposome, 186RNL) for the treatment of leptomeningeal metastases (LM): Update on Phase 1 dose escalation study. (SABCS 2024) - Nov 2, 2024 - Abstract #PS14-01; SESS-2271; Pres time: Dec 13, 2024; 07:00 AM - 07:30 AM; Location: Stars at Night 3-4; "A single dose of 186RNL for patients with LM has been well-tolerated, with high absorbed doses to the treatment area, acceptable organ doses, and promising clinical improvement and reductions in tumor cell count. Phase 2 is expected to begin enrollment by Q4 2024. Additionally, based on these data, a Phase 1 multidose study is planned to be initiated this year."
P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Triple Negative Breast Cancer • ER • HER-2 • PGR
|